Liraglutide
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Novo Nordisk · Phase 3 · Completed · Enrollment 3731
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68) | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Placebo, no Pre-diabetes | 78 participants | 25 participants | 46 participants | n/r | n/r |
| Liraglutide 3.0mg, Pre-diabetes | n/r | n/r | n/r | n/r | n/r |
| Liraglutide Placebo, Pre-diabetes | 128 participants | 42 participants | 107 participants | n/r | n/r |
| Liraglutide 3.0 mg (56-Week) | 622 participants | 300 participants | 388 participants | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.